# A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT06235229** · PHASE1,PHASE2 · RECRUITING · sponsor: **Gracell Biotechnologies (Shanghai) Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** GC012F

## Key facts

- **NCT ID:** NCT06235229
- **Lead sponsor:** Gracell Biotechnologies (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-26
- **Primary completion:** 2026-03-02
- **Final completion:** 2026-03-02
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235229, "A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06235229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*